Leonard B Seeff

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Herbal hepatotoxicity
    Leonard B Seeff
    National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 31 Center Drive, Room 9A27, Bethesda, MD 20892, USA
    Clin Liver Dis 11:577-96, vii. 2007
  2. ncbi request reprint Natural history of chronic hepatitis C
    Leonard B Seeff
    Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Disease, National Institutes of Health, Bethesda, MD, USA
    Hepatology 36:S35-46. 2002
  3. pmc Coffee consumption is associated with response to peginterferon and ribavirin therapy in patients with chronic hepatitis C
    Neal D Freedman
    Nutritional Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, Maryland 20852, USA
    Gastroenterology 140:1961-9. 2011
  4. pmc Predicting clinical outcomes using baseline and follow-up laboratory data from the hepatitis C long-term treatment against cirrhosis trial
    Marc G Ghany
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892 1800, USA
    Hepatology 54:1527-37. 2011
  5. pmc An IL28B genotype-based clinical prediction model for treatment of chronic hepatitis C
    THOMAS R O'BRIEN
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, United States of America
    PLoS ONE 6:e20904. 2011
  6. pmc Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial
    Tania Mara Welzel
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    Hepatology 49:1847-58. 2009
  7. ncbi request reprint Complementary and alternative medicine (CAM) for the treatment of chronic hepatitis B and C: a review
    Apurva A Modi
    The National Institute of Diabetes and Digestive and Kidney Diseases, The National Institute of Health, Bethesda, MD, USA
    Antivir Ther 12:285-95. 2007
  8. doi request reprint The history of the "natural history" of hepatitis C (1968-2009)
    Leonard B Seeff
    National Institute of Diabetes and Digestive, and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Liver Int 29:89-99. 2009
  9. ncbi request reprint Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial
    Leonard B Seeff
    Division of Digestive Diseases and Nutrition, National Institutes of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    Hepatology 47:605-12. 2008
  10. ncbi request reprint National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002
    Leonard B Seeff
    Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Hepatology 36:S1-2. 2002

Collaborators

Detail Information

Publications31

  1. ncbi request reprint Herbal hepatotoxicity
    Leonard B Seeff
    National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 31 Center Drive, Room 9A27, Bethesda, MD 20892, USA
    Clin Liver Dis 11:577-96, vii. 2007
    ..Although many of them are clearly implicated, there are some, particularly those identified solely through an occasional case report, for which the relationship is uncertain...
  2. ncbi request reprint Natural history of chronic hepatitis C
    Leonard B Seeff
    Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Disease, National Institutes of Health, Bethesda, MD, USA
    Hepatology 36:S35-46. 2002
    ..Several host-related and extraneous factors probably affect the natural history...
  3. pmc Coffee consumption is associated with response to peginterferon and ribavirin therapy in patients with chronic hepatitis C
    Neal D Freedman
    Nutritional Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, Maryland 20852, USA
    Gastroenterology 140:1961-9. 2011
    ..However, its relationship with therapy for hepatitis C virus infection has not been evaluated...
  4. pmc Predicting clinical outcomes using baseline and follow-up laboratory data from the hepatitis C long-term treatment against cirrhosis trial
    Marc G Ghany
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892 1800, USA
    Hepatology 54:1527-37. 2011
    ..A model that included baseline platelet count and albumin as well as severe worsening of AST/ALT ratio and albumin was the best predictor of liver-related outcomes...
  5. pmc An IL28B genotype-based clinical prediction model for treatment of chronic hepatitis C
    THOMAS R O'BRIEN
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, United States of America
    PLoS ONE 6:e20904. 2011
    ..Using data from the HALT-C Trial, we developed a model to predict a patient's probability of SVR based on IL28B genotype and clinical variables...
  6. pmc Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial
    Tania Mara Welzel
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    Hepatology 49:1847-58. 2009
    ..51; P = 0.05) and a strong relationship among African American patients; all 10 with SVR who were genotyped for TYK2 -2256 carried the A variant compared with 68 of 120 (57%) nonresponders (P = 0.006)...
  7. ncbi request reprint Complementary and alternative medicine (CAM) for the treatment of chronic hepatitis B and C: a review
    Apurva A Modi
    The National Institute of Diabetes and Digestive and Kidney Diseases, The National Institute of Health, Bethesda, MD, USA
    Antivir Ther 12:285-95. 2007
    ..Five herbals used in the past to treat viral hepatitis are reviewed and evaluated for the quality of their studies and mention is made of herbals known to have adverse effects...
  8. doi request reprint The history of the "natural history" of hepatitis C (1968-2009)
    Leonard B Seeff
    National Institute of Diabetes and Digestive, and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Liver Int 29:89-99. 2009
    ..Differing strategies have been used to determine the natural history, the descriptions and results of which are presented in this review...
  9. ncbi request reprint Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial
    Leonard B Seeff
    Division of Digestive Diseases and Nutrition, National Institutes of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    Hepatology 47:605-12. 2008
    ..Because its use among these HALT-C participants was self-motivated and uncontrolled, however, only a well-designed prospective study can determine whether silymarin provides benefit to persons with chronic hepatitis C...
  10. ncbi request reprint National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002
    Leonard B Seeff
    Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Hepatology 36:S1-2. 2002
  11. ncbi request reprint Peginterferon and ribavirin for chronic hepatitis C
    Jay H Hoofnagle
    Liver Disease Research Branch, Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA
    N Engl J Med 355:2444-51. 2006
  12. ncbi request reprint Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002
    Leonard B Seeff
    National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Health, 31A Center Drive, Room 9A27, Building 37, Bethesda, MD 20892, USA
    Clin Liver Dis 7:261-87. 2003
    ....
  13. pmc Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial
    Leonard B Seeff
    Division of Digestive Diseases and Nutrition, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892, USA
    Clin Gastroenterol Hepatol 8:877-83. 2010
    ..The safety and complications of liver biopsy were examined in patients with hepatitis C-related bridging fibrosis or cirrhosis who were enrolled in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis trial...
  14. ncbi request reprint Introduction: The burden of hepatocellular carcinoma
    Leonard B Seeff
    Liver Diseases Research Branch, Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Gastroenterology 127:S1-4. 2004
  15. ncbi request reprint Hepatitis C infection and injection drug use: the role of hepatologists in evolving treatment efforts
    Thomas F Kresina
    Center on AIDS and Other Medical Consequences of Drug Abuse, National Institute on Drug Abuse, Department of Health and Human Services, Bethesda, MD 20892, USA
    Hepatology 40:516-9. 2004
    ..The current article addresses the newly evolving, complex issues in the medical management of hepatitis C and injection drug use...
  16. pmc Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C
    Neal D Freedman
    Nutritional Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, MD 20852, USA
    Hepatology 50:1360-9. 2009
    ..Tea intake was not associated with outcomes. CONCLUSION: In a large prospective study of participants with advanced hepatitis C-related liver disease, regular coffee consumption was associated with lower rates of disease progression...
  17. ncbi request reprint Hepatitis C and renal disease: an update
    Catherine M Meyers
    Division of Kidney, National Institute of Diabetes and Digestive and Kidney Diseases, The National Institutes of Health, Bethesda, MD 20892, USA
    Am J Kidney Dis 42:631-57. 2003
    ..There are significant needs in both basic and clinical research in the pathogenesis, natural history, prevention, and therapy for hepatitis C in patients with renal disease...
  18. ncbi request reprint Efforts to define the natural history of chronic hepatitis C continue
    Marc G Ghany
    Clin Gastroenterol Hepatol 4:1190-2. 2006
  19. ncbi request reprint Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial
    Gregory T Everson
    Section of Hepatology, Division of Gastroenterology and Hepatology, University of Colorado School of Medicine, Denver, CO, USA
    Hepatology 44:1675-84. 2006
    ..In conclusion, disease severity is a major independent determinant of rate of SVR in patients with advanced chronic hepatitis C. New strategies are needed to optimize antiviral therapy in these "difficult-to-cure" patients...
  20. ncbi request reprint More severe parenchymal injury in chronic hepatitis C acquired by recent injection drug use
    Matthew M Yeh
    Department of Pathology, George Washington University School of Medicine, Washington, DC, and the Department of Medicine, Veterans Affairs Medical Center, Washington, DC, USA
    J Clin Gastroenterol 39:722-7. 2005
    ..The availability of material from a cohort of patients who had liver biopsy for IDU-related hepatitis C in the 1970s enabled us to compare the histology with that of current patients...
  21. ncbi request reprint Analysis of hepatitis C virus quasispecies transmission and evolution in patients infected through blood transfusion
    Tomasz Laskus
    Department of Medicine, Mayo Clinic Scottsdale, Scottsdale, Arizona, USA
    Gastroenterology 127:764-76. 2004
    ..Studies on hepatitis C virus (HCV) quasispecies dynamics in the natural course of infection are rare owing to difficulties in obtaining samples from the early phase of infection...
  22. ncbi request reprint Viral load as a predictor of progression of chronic hepatitis C?
    Theo Heller
    Hepatology 42:1261-3. 2005
  23. pmc Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation
    Norah A Terrault
    Department of Medicine, Division of Gastroenterology, University of California at San Francisco, San Francisco, CA, USA
    Liver Transpl 13:122-9. 2007
    ..Important predictors of graft loss in HCV-infected patients were limited LDLT experience, pretransplant HCC, and higher MELD at transplantation...
  24. ncbi request reprint A framework for management of hepatitis C in prisons
    Anne C Spaulding
    Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Ann Intern Med 144:762-9. 2006
    ....
  25. ncbi request reprint Drug-induced liver injury: summary of a single topic clinical research conference
    Paul B Watkins
    University of North Carolina, Chapel Hill, NC, USA
    Hepatology 43:618-31. 2006
    ..The presentations spanned many different areas of DILI, and included novel data concerning mechanisms of hepatotoxicity, new "omics" approaches, and the challenges of improving causation assessment...
  26. ncbi request reprint Is cirrhosis an inevitable consequence of chronic hepatitis C virus infection?
    Leonard B Seeff
    Clin Gastroenterol Hepatol 3:840-2. 2005
  27. ncbi request reprint Natural history of hepatitis C
    David L Thomas
    Johns Hopkins School of Medicine, 1503 E Jefferson Street, Baltimore, MD 21231, USA
    Clin Liver Dis 9:383-98, vi. 2005
    ..The ability to detect persons at highest risk of progression remains incomplete and represents an important future challenge in the understanding of the natural history of hepatitis C...
  28. ncbi request reprint Testing for hepatitis C virus infection should be routine for persons at increased risk for infection
    Miriam J Alter
    Division of Viral Hepatitis, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Ann Intern Med 141:715-7. 2004
    ....
  29. ncbi request reprint Diagnosis, management, and treatment of hepatitis C
    Doris B Strader
    Fletcher Allen Health Care University of Vermont College of Medicine, Burlington, VA, USA
    Hepatology 39:1147-71. 2004
  30. ncbi request reprint Low-positive anti-hepatitis C virus enzyme immunoassay results: an important predictor of low likelihood of hepatitis C infection
    D Robert Dufour
    Pathology and Laboratory Medicine Service, Veterans Affairs Medical Center, Washington, DC 20422, USA
    Clin Chem 49:479-86. 2003
    ..Several studies, mainly in blood donors, have found that specimens with low signal/cutoff (S/C) ratios are commonly negative when tested with a recombinant immunoblot assay (RIBA) or for HCV RNA...
  31. ncbi request reprint Use of complementary and alternative medicine in patients with liver disease
    Doris B Strader
    Division of Gastroenterology, Hepatology and Nutrition, Veterans Affairs Medical Center, Washington, DC 20422, USA
    Am J Gastroenterol 97:2391-7. 2002
    ..S. population. Its use among patients with chronic liver disease has not been well defined. Toward that end, we surveyed patients in six geographically diverse liver disease clinics in the United States for use of CAM...